Literature DB >> 11495720

The interaction of dystrophin with beta-dystroglycan is regulated by tyrosine phosphorylation.

J L Ilsley1, M Sudol, S J Winder.   

Abstract

Dystrophin and the dystrophin-associated protein complex (DAPC) have recently been implicated in cell signalling events. These proteins are ideally placed to transduce signals from the extracellular matrix (ECM) to the cytoskeleton. Here we show that beta-dystroglycan is tyrosine-phosphorylated in C2/C4 mouse myotubes. Tyrosine phosphorylation was detected by mobility shifts on SDS-polyacrylamide gels (SDS-PAGE) and confirmed by immunoprecipitation and two-dimensional gel electrophoresis. The potential functional significance of this tyrosine phosphorylation was investigated using peptide 'SPOTs' assays. Phosphorylation of tyrosine in the 15 most C-terminal amino acids of beta-dystroglycan disrupts its interaction with dystrophin. The tyrosine residue in beta-dystroglycan's WW-binding motif PPPY appears to be the most crucial in disrupting the beta-dystroglycan-dystrophin interaction. beta-dystroglycan forms the essential link between dystrophin and the rest of the DAPC. This regulation by tyrosine phosphorylation may have implications in the pathogenesis and treatment of Duchenne's muscular dystrophy (DMD).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11495720     DOI: 10.1016/s0898-6568(01)00188-7

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  38 in total

Review 1.  Syntrophins entangled in cytoskeletal meshwork: Helping to hold it all together.

Authors:  Sahar S Bhat; Roshia Ali; Firdous A Khanday
Journal:  Cell Prolif       Date:  2018-12-04       Impact factor: 6.831

2.  Direct interaction of beta-dystroglycan with F-actin.

Authors:  Yun-Ju Chen; Heather J Spence; Jacqueline M Cameron; Thomas Jess; Jane L Ilsley; Steven J Winder
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

3.  Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle.

Authors:  Jung Hae Yoon; Eric Johnson; Rui Xu; Laura T Martin; Paul T Martin; Federica Montanaro
Journal:  J Proteome Res       Date:  2012-07-30       Impact factor: 4.466

4.  Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse.

Authors:  Gaynor Miller; Chris J Moore; Rebecca Terry; Tracy La Riviere; Andrew Mitchell; Robert Piggott; T Neil Dear; Dominic J Wells; Steve J Winder
Journal:  Hum Mol Genet       Date:  2012-07-18       Impact factor: 6.150

5.  Characterization of human alpha-dystrobrevin isoforms in HL-60 human promyelocytic leukemia cells undergoing granulocytic differentiation.

Authors:  Agné Kulyte; Ruta Navakauskiene; Grazina Treigyte; Arunas Gineitis; Tomas Bergman; Karl-Eric Magnusson
Journal:  Mol Biol Cell       Date:  2002-12       Impact factor: 4.138

6.  Dystroglycan, a scaffold for the ERK-MAP kinase cascade.

Authors:  Heather J Spence; Amardeep S Dhillon; Marian James; Steven J Winder
Journal:  EMBO Rep       Date:  2004-04-08       Impact factor: 8.807

7.  The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin.

Authors:  Jung Hae Yoon; Kumaran Chandrasekharan; Rui Xu; Matthew Glass; Neha Singhal; Paul T Martin
Journal:  Mol Cell Neurosci       Date:  2009-05-12       Impact factor: 4.314

Review 8.  Biological role of dystroglycan in Schwann cell function and its implications in peripheral nervous system diseases.

Authors:  Toshihiro Masaki; Kiichiro Matsumura
Journal:  J Biomed Biotechnol       Date:  2010-06-15

9.  Dystroglycan versatility in cell adhesion: a tale of multiple motifs.

Authors:  Chris J Moore; Steve J Winder
Journal:  Cell Commun Signal       Date:  2010-02-17       Impact factor: 5.712

10.  Ligation of alpha-dystroglycan on podocytes induces intracellular signaling: a new mechanism for podocyte effacement?

Authors:  Nils P J Vogtländer; Henk Jan Visch; Marinka A H Bakker; Jo H M Berden; Johan van der Vlag
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.